Journal of Shandong University (Health Sciences) ›› 2024, Vol. 62 ›› Issue (4): 24-30.doi: 10.6040/j.issn.1671-7554.0.2024.0184

• Clinical Medicine • Previous Articles     Next Articles

Subcellular localization pattern of bromodomain containing 9 in colorectal cancer and its clinical significance

LIU Chuncheng1, LIU Xiaohan1, WEI Yanruoxue1, LI Ziqi1, LIU Yukun1,2, ZHAO Ran1,2   

  1. 1. Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China;
    2. Department of Pathology, Affiliated Hospital of Jining Medical University, Jining 272029, Shandong, China
  • Published:2024-05-16

PDF (PC)

265

Abstract: Objective To investigate the protein expression level, subcellular localization pattern and clinical significance of bromodomain containing 9(BRD9)in colorectal cancer(CRC). Methods Surgical resection specimens of CRC were collected, and immunohistochemistry(EnVision method)was used to detect BRD9 protein expression and subcellular localization. The relationship between BRD9 expression and clinicopathological features and prognosis of CRC patients was analyzed. Results Among 508 CRC tissue specimens, BRD9 was overexpressed in 71.46%(363/508)of patients, and 80.31%(408/508)of patients showed nuclear positive staining in immunohistochemistry for BRD9. The expression of BRD9 was correlated with tumor size(P=0.025), lymph node metastasis(P=0.004), nerve invasion(P=0.043), differentiation grade(P=0.017)and TNM stage(P=0.002). The subcellular localization of BRD9 was correlated with lymph node metastasis(P=0.040)and TNM stage(P=0.026). The difference was statistically significant. Meanwhile, BRD9 high expression served as an independent poor prognostic factor(HR=1.994, P=0.002). More important, in patients with BRD9 low expression, cytoplasmic BRD9 expression was an independent poor prognostic factor of patients(HR=8.056, P=0.001). Conclusion The subcellular localization of BRD9 is heterogeneous in CRC patients. The high expression and cytoplasmic localization of BRD9 are related to the occurrence and development of CRC, and could be used as an independent predictor for the prognosis of CRC patients.

Key words: Colorectal cancer, Immunohistochemistry, Bromodomain containing 9, Subcellular localization, Prognosis

CLC Number: 

  • R735.3
[1] Morgan E, Arnold M, Gini A,et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN [J]. Gut, 2023, 72(2):338-344.
[2] Li N, Lu B, Luo C, et al. Incidence, mortality, survival, risk factor and screening of colorectal cancer: a comparison among China, Europe, and northern America [J].Cancer Lett,2021, 522: 255-268.doi: 10.1016/j.canlet.2021.09.034.
[3] Mauri G, Sartore-Bianchi A, Russo AG, et al. Early-onset colorectal cancer in young individuals [J]. Mol Oncol, 2019, 13(2): 109-131.
[4] Ali MM, Naz S, Ashraf S, et al. Epigenetic modulation by targeting bromodomain containing protein 9(BRD9): Its therapeutic potential and selective inhibition [J]. Int J Biol Macromol, 2023, 230: 123428. doi: 10.1016/j.ijbiomac.2023.123428.
[5] Chen P, Du R, Chang Z, et al. Bromodomain-containing protein 9 activates proliferation and epithelial-mesenchymal transition of colorectal cancer via the estrogen pathway in vivo and in vitro [J]. J Gastrointest Oncol,2023, 14(2): 980-996.
[6] Zhao R, Liu Y, Wu C, et al. BRD7 promotes cell proliferation and tumor growth through stabilization of c-Myc in colorectal cancer [J]. Front Cell Dev Biol, 2021, 9: 659392. doi: 10.3389/fcell.2021.659392.
[7] Liu Y, Zhao R, Wei Y, et al. BRD7 expression and c-Myc activation forms a double-negative feedback loop that controls the cell proliferation and tumor growth of nasopharyngeal carcinoma by targeting oncogenic miR-141 [J]. J Exp Clin Cancer Res, 2018, 37(1): 64. doi: 10.1186/s13046-018-0734-2.
[8] Chen Y, Gao Z, Mohd-Ibrahim I, et al. Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours [J]. Clin Transl Med, 2024, 14(2): e1543. doi: 10.1002/ctm2.1543.
[9] Ahmed NS, Gatchalian J, Ho J, et al. BRD9 regulates interferon-stimulated genes during macrophage activation via cooperation with BET protein BRD4 [J]. Proc Natl Acad Sci U S A, 2022, 119(1): e2110812119. doi: 10.1073/pnas.2110812119.
[10] Kurata K, Samur MK, Liow P, et al. BRD9 degradation disrupts ribosome biogenesis in multiple myeloma [J]. Clin Cancer Res, 2023, 29(9): 1807-1821.
[11] Alpsoy A, Utturkar SM, Carter BC, et al. BRD9 is a critical regulator of androgen receptor signaling and prostate cancer progression [J]. Cancer Res, 2021, 81(4): 820-833.
[12] Liu T, Li Q, Jin Q, et al. Targeting HMGB1: A potential therapeutic strategy for chronic kidney disease [J]. Int J Biol Sci, 2023, 19(15): 5020-5035.
[13] Hao SH, Ma XD, Xu L, et al. Dual specific phosphatase 4 suppresses ferroptotosis and enhances sorafenib resistance in hepatocellular carcinoma [J]. Drug Resist Updat, 2024, 73: 101052. doi: 10.1016/j.drup.2024.101052.
[14] Crodian JS, Weldon BM, Tseng YC, et al. Nuclear trafficking dynamics of Bromodomain-containing protein 7(BRD7), a switch/sucrose non-fermentable(SWI/SNF)chromatin remodelling complex subunit, in porcine oocytes and cleavage-stage embryos [J]. Reprod Fertil Dev, 2019, 31(9): 1497-1506.
[15] Vivenza D, Garrone O, Brizio R, et al. Expression and subcellular localization of the bromodomain-containing protein 7 is a prognostic biomarker in breast cancer [J]. Anticancer Drugs, 2020, 31(4): 423-430.
[16] Dariya B, Aliya S, Merchant N, et al. Colorectal cancer biology, diagnosis, and therapeutic approaches [J]. Crit Rev Oncog, 2020, 25(2): 71-94.
[17] Zygulska AL, Pierzchalski P. Novel diagnostic biomarkers in colorectal cancer [J]. Int J Mol Sci, 2022, 23(2): 852. doi: 10.3390/ijms23020852.
[18] Chen H, Zhai C, Xu X, et al. Multilevel heterogeneity of colorectal cancer liver metastasis [J]. Cancers(Basel), 2023, 16(1): 59. doi: 10.3390/cancers16010059.
[19] Punt CJ, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer [J]. Nat Rev Clin Oncol, 2017, 14(4): 235-246.
[20] Saoudi González N, Salvà F, Ros J, et al. Unravelling the complexity of colorectal cancer: heterogeneity, clonal evolution, and clinical implications [J]. Cancers(Basel),2023,15(16): 4020. doi: 10.3390/cancers15164020.
[21] Nguyen LH, Goel A, Chung DC. Pathways of colorectal carcinogenesis [J]. Gastroenterology, 2020, 158(2): 291-302.
[22] Hong SN. Genetic and epigenetic alterations of colorectal cancer [J]. Intest Res, 2018, 16(3): 327-337.
[23] Singh MP, Rai S, Suyal S, et al. Genetic and epigenetic markers in colorectal cancer screening: recent advances [J]. Expert Rev Mol Diagn, 2017, 17(7): 665-685.
[24] Pan Z, Zhao Y, Wang X, et al. Targeting bromodomain-containing proteins: research advances of drug discovery [J]. Mol Biomed, 2023, 4(1): 13. doi: 10.1186/s43556-023-00127-1.
[25] Marmorstein R, Zhou MM. Writers and readers of histone acetylation: structure, mechanism, and inhibition [J]. Cold Spring Harb Perspect Biol, 2014, 6(7): a018762. doi: 10.1101/cshperspect.a018762.
[26] Fujisawa T, Filippakopoulos P. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer [J]. Nat Rev Mol Cell Biol, 2017, 18(4): 246-262.
[1] LI Ziqi, WEI Yanruoxue, LIU Xiaohan, LIU Chuncheng, ZHAO Ran, LIU Yukun. The functional role and clinical significance of lncRNA HEATR3-AS1 in colorectal cancer tumorigenesis and progression [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 108-115.
[2] LIU Baoguo, SONG Xiang, ZHAO Xiaowen, MAO Yali. Application value of serum STAT5B and NKAIN1 mRNA detection in breast cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(7): 68-74.
[3] WANG Lei, CHANG Xiao, WANG Zimeng, LI Jiaojiao, CUI Shujun, YANG Fei, ZHU Yuexiang. Predictive value of intratumoral and peritumoral DCE-MRI imaging histology for progression-free survival in patients with cervical cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 45-54.
[4] JIA Ruoxi, LYU Li, LIU Hanyun, WU Yinping, LI Fengcai, ZHAO Zehua, WANG Kai, FAN Yuchen. Diagnostic value of blood cell count-related biomarkers in predicting 28-day mortality in acute-on-chronic hepatitis b liver failure [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 89-99.
[5] DU Xue, LI Chunxia, LIU Yunxia, ZHANG Tao. Dynamic prediction model for the colorectal cancer patients prognosis based on MFPC-Cox [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 101-110.
[6] YANG Weifang, XU Hong, LIU Yuantao, ZHAO Huichen. Mechanism of thyroid-stimulating immunoglobulin in Graves disease recurrence and clinical significance [J]. Journal of Shandong University (Health Sciences), 2025, 63(4): 116-121.
[7] WANG Gang, XU Pengyan, ZHAO Xuan, WANG Haifeng, GE Miaomiao, PAN Huafeng, JIANG Zhiwei. Effect of ω-3 polyunsaturated fatty acids on recovery of autonomic nervous system and intestinal function after laparoscopic colorectal cancer surgery [J]. Journal of Shandong University (Health Sciences), 2025, 63(2): 36-42.
[8] CUI Qianqian, LI Jinpeng, WU Yudan, HOU Zhiping, SUN Weiluo, CUI Panpan, HE Peiyuan. Clinical value of fecal miRNA for non-invasive screening of advanced colorectal adenomas [J]. Journal of Shandong University (Health Sciences), 2025, 63(2): 43-50.
[9] CHANG Yu, HU Yunfeng, WANG Huifeng, GUO Jing, ZHANG Tiao, HAO Yaqin, LIU Yu. A mendelian randomization study on the association between appendectomy and the risk of colorectal cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(2): 77-83.
[10] YU Jing, WANG Gang, WANG Ye, SHAO Mingyue, PAN Huafeng, GE Miaomiao, WANG Haifeng, JIANG Zhiwei. Effect of Yiqidaozhi Decoction in postoperative intestinal recovery of colorectal cancer patients based on I-FEED scoring system [J]. Journal of Shandong University (Health Sciences), 2025, 63(12): 35-43.
[11] LIU Wenzhao, ZHANG Yuan, MA Xiangping, WEI Fengtao, BU Peili. Correlation between the pre-endothelial activation and stress index and the mortality risk of patients with heart failure [J]. Journal of Shandong University (Health Sciences), 2025, 63(11): 27-35.
[12] CHEN Wenliang, WANG Huanhuan, HAO Jinjin, GONG Rui, ZHAO Qiang, ZHANG Fei, GAO Lei, DONG Jingxun. The role of lncRNA PVT1 in prognostic assessment and malignant progression of gastric cancer: a study based on nomogram model and functional cellular experiments [J]. Journal of Shandong University (Health Sciences), 2025, 63(10): 61-71.
[13] GUO Shuhua, FAN Yang, TIAN Feng, WANG Chuanxin, DU Lutao, LI Peilong, GUO Xing, XU Shuo. Role of microfibril-associated protein 3 in regulating mesenchymal transition of glioma stem cells [J]. Journal of Shandong University (Health Sciences), 2024, 62(6): 9-16.
[14] WANG Xiao, KONG Wenru, CUI Weiliang, WANG Shuqi. Alstonia mairei total alkaloids enhance the sensitivity of colorectal cancer to 5-fluorouracil chemotherapy [J]. Journal of Shandong University (Health Sciences), 2024, 62(6): 30-37.
[15] WEI Yanruoxue, LI Ziqi, LIU Chuncheng, LIU Xiaohan, ZHAO Ran, LIU Yukun. Intratumor heterogeneity of SP1 expression in colorectal cancer and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2024, 62(5): 89-94.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd